Company intelligence / Profile preview

Pragma Bio

South San Francisco, California, United Statespragmabio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Pragma Bio has developed an AI-driven drug discovery platform focused on identifying and developing novel small molecules from the human microbiome to modulate immune responses. The company leverages bioinformatics, synthetic biology, and pharmacology to mine biosynthetic gene clusters from clinically relevant sources. No clinical results have been published as of June 2025.

Therapeutic areas: Immunology
Modalities: Small moleculeBiologic (via synthetic biology approaches)Synthetic oligonucleotide
Industry: Biotech

Partnerships

Collaborations with leading biopharma and research organizations are mentioned but not specified by name.

Beyond the preview

Go deeper on Pragma Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pragma Bio.

Explore the full profile